# Table of Contents

## Highlights of This Issue

2213

## REVIEW

- **New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects**
  Guadalupe Aparicio-Gallego, Moisés Blanco, Ángel Figueroa, Rosario García-Campelo, Manuel Valladares-Ayerbes, Enrique Grande-Pulido, and Luis Antón-Aparicio

## THERAPEUTIC DISCOVERY

- **Artesunate Induces Oxidative DNA Damage, Sustained DNA Double-Strand Breaks, and the ATM/ATR Damage Response in Cancer Cells**
  Nicole Berdelle, Teodora Nikolova, Steve Quiros, Thomas Efferth, and Bernd Kaina

- **Direct Role of Adiponectin and Adiponectin Receptors in Endometrial Cancer: *In Vitro* and *Ex Vivo* Studies in Humans**
  Hyun-Seuk Moon, John P. Chamberland, Konstantinos Aronis, Sofia Tseleisi-Balafouta, and Christos S. Mantzoros

- **Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma**
  Cheri Cloninger, Andrew Bernath, Tariq Bashir, Brent Holmes, Nicholas Artinian, Teresa Ruegg, Lauren Anderson, Janine Masri, Alan Lichtenstein, and Joseph Gera

- **Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype**
  Michael F. Emmons, Anthony W. Gebhard, Rajesh R. Nair, Rachid Baz, Mark L. McLaughlin, Anne E. Cress, and Lori A. Hazlehurst

## PRECLINICAL DEVELOPMENT

- **Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1**
  Keith D. Tardif, Aaron Rogers, Jared Cassiano, Bruce L. Roth, Daniel M. Cimbora, Rena McKinnon, Ashley Peterson, Thomas B. Douce, Rosann Robinson, Irene Dorweiler, Thaylon Davis, Mark A. Hess, Kirill Ostanin, Damon I. Papac, Vijay Baichwal, Ian McAlexander, J. Adam Willardsen, Michael Saunders, Hoarau Christophe, D. Vijay Kumar, Daniel A. Wettstein, Robert O. Carlson, and Brandi L. Williams

- **Integrin α6high Cell Population Functions as an Initiator in Tumorigenesis and Relapse of Human Liposarcoma**
  Lu Wang, Lingxian Wang, Yanhong Gu, Yongqian Shu, Yan Shen, and Qiang Xu

- **Micelle-Encapsulated Thiostrepton as an Effective Nanomedicine for Inhibiting Tumor Growth and for Suppressing FOXM1 in Human Xenografts**
  Ming Wang and Andrei L. Gartel

- **Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth**

---

Molecular Cancer Therapeutics

The Cancer Drug Development Journal: From Concept to Clinic

December 2011 - Volume 10 - Number 12

www.aacrjournals.org
Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer

Yixian Zhang, Stephen Castaneda, Melissa Dumble, Maoliang Wang, Mary Mileski, Zhengxing Qu, Steven Kim, Victoria Shi, Patricia Kraft, Ying Gao, Jenny Pak, Puja Sapra, Raja Bandaru, Hong Zhao, Robert L. Vessella, Ivan D. Horak, and Lee M. Greenberger

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice


Differential Expression of Uridine Phosphorylase in Tumors Contributes to an Improved Fluoropyrimidine Therapeutic Activity

Deliang Cao, Amy Ziemba, James McCabe, Ruilan Yan, Laxiang Wan, Bradford Kim, Michael Gach, Stuart Flynn, and Giuseppe Pizzorno

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo


Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models

Jae-Ho Cheong, Eun Sung Park, Jiyoung Liang, Jennifer B. Dennison, Dimitra Tsavachidou, Catherine Nguyen-Charles, Kwai Wa Cheng, Hassan Hall, Dong Zhang, Yiling Lu, Murali Ravoori, Vikas Kundra, Jaffer Ajani, Ju-Seog Lee, Waun Ki Hong, and Gordon B. Mills

Vitamin E ô-Tocotrienol Augments the Antitumor Activity of Gemcitabine and Suppresses Constitutive NF-κB Activation in Pancreatic Cancer

Kazim Husain, Rony A. Francois, Teruo Yamauchi, Marta Perez, Said M. Sebti, and Mokenge P. Malafa
Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin–like Growth Factor I Receptor Monoclonal Antibody
Dong Hoon Shin, Hye-Young Min, Adel K. El-Naggar, Scott M. Lippman, Bonnie Glisson, and Ho-Young Lee

ABOUT THE COVER

Human lung microvascular cells cocultured with human diploid fibroblasts form extensive networks of tubules in response to VEGF that can be visualized by immunostaining for CD31, an endothelial cell marker. In the presence of cabozantinib (XL184), a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2, it was found that tubule formation was inhibited in the absence of cytotoxicity. Similarly, cabozantinib inhibited tubule formation in response to conditioned media derived from tumor cell cultures, suggesting that secreted tumor cell-derived proangiogenic growth factors are unable to circumvent inhibition of tubule formation by cabozantinib. For details, see article by Yakes and colleagues on page 2298.
# Molecular Cancer Therapeutics

10 (12)


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://mct.aacrjournals.org/content/10/12">http://mct.aacrjournals.org/content/10/12</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>